Inside the Mind of a Healthcare Market Research Leader: A Conversation with Dr. Priya Mehta on Patient-Centric Research Design
Introduction
The healthcare and life sciences market research sector is navigating extraordinary complexity. From the post-pandemic reconfiguration of care delivery to the AI-driven diagnostics revolution, from biosimilar market disruptions to the surging demand for real-world evidence (RWE), the pressure on researchers to generate decision-quality intelligence has never been greater. We sat down with Dr. Priya Mehta, a veteran healthcare market researcher with 18 years of experience spanning pharmaceutical brand strategy, medical device adoption studies, and health system stakeholder engagement across the U.S., EU, and Asia-Pacific markets, to discuss the state of healthcare research and where the discipline is headed.
"Healthcare market research is fundamentally different from any other sector because the stakes of getting it wrong are not commercial — they are clinical. Bad research doesn't just cost a company money; it can ultimately influence decisions that affect patient outcomes."
— Dr. Priya Mehta
On the Current State of the Healthcare Research Market
Q: Dr. Mehta, the global healthcare market is enormous — where do you see the most significant research demand right now?
The sheer scale is striking. The global healthcare market is on track to exceed $665 billion in research and development spending globally by 2024, and the market intelligence ecosystem that supports it — clinical research organizations, market research firms, consulting groups, health economics specialists — has grown proportionally. But the demand isn't evenly distributed.
Right now, the areas generating the most intense research activity are oncology — which has been dominant for years and shows no signs of slowing, given that cancer represents over 40% of total pharma R&D spend — and increasingly, metabolic disease. The GLP-1 receptor agonist revolution, driven by Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound, has triggered a tsunami of market research across the entire obesity and type 2 diabetes landscape. We're seeing unprecedented demand for patient journey studies, payer access research, and physician behavior analysis in that space.
Q: And what about the broader structural shifts in how care is delivered — telehealth, value-based care models?
These are enormously consequential for how we design research. The rapid expansion of telehealth during COVID-19 — utilization increased by 38-fold in the early months of the pandemic according to McKinsey — has permanently altered physician-patient interaction patterns. It's also created new stakeholder personas that we as researchers must account for. The Chief Medical Information Officer (CMIO), the Virtual Care Director, the Population Health Manager — these roles have grown in institutional influence, and they're increasingly relevant audiences for medical device companies, digital health vendors, and pharmaceutical brands trying to understand how their products fit into care pathways.
Value-based care transitions have similarly complicated physician segmentation. Understanding how a cardiologist in an Accountable Care Organization (ACO) makes prescribing decisions versus a colleague in a traditional fee-for-service private practice requires completely different research frameworks. The financial incentive structures are different, the formulary pressures are different, the patient population risk profiles are different.
On Research Methodology in Healthcare Settings
Q: What methodological approaches do you find most effective for healthcare research — particularly when working with physician or patient populations?
I'll be honest — I'm a pluralist when it comes to methods. I don't believe any single methodology has a monopoly on truth in healthcare research. That said, I want to highlight a few that I think are genuinely underutilized.
First, digital ethnography with patients. The online health communities — the lupus forums, the rare disease Facebook groups, the psoriasis Reddit threads — represent an extraordinary reservoir of authentic patient experience data. Platforms like Treato and PatientLikeMe, combined with natural language processing tools, enable researchers to analyze thousands of patient narratives at scale. When we use these alongside structured qualitative interviews, we get a richness of understanding about treatment burden, medication adherence triggers, and unmet needs that traditional focus groups rarely produce.
Second, discrete choice experiments (DCE) for treatment attribute valuation. Whether we're trying to understand how oncologists trade off efficacy against tolerability, or how patients value different attributes of a chronic disease therapy — administration frequency, side effect profiles, out-of-pocket cost — DCE is the methodological gold standard. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) has published excellent guidance on DCE design in healthcare contexts that I'd recommend to any researcher in this space.
Q: What about the rise of real-world evidence? How does that intersect with traditional market research?
This is one of the most important conversations happening in our field right now. Real-world evidence — data drawn from electronic health records, claims databases, pharmacy dispensing records, patient registries — is increasingly being used not just for regulatory submissions but for commercial market intelligence. The U.S. FDA's Real-World Evidence Framework and the EMA's similar guidance have legitimized RWE in ways that have changed what clients expect from research providers.
The intersection with traditional market research is fascinating. RWE tells you what physicians actually prescribe; primary research tells you why. Combining claims data analysis — through platforms like IQVIA's Longitudinal Prescription (LRx) database or Symphony Health — with qualitative physician interviews creates a powerful analytical loop. We can identify an anomaly in prescribing behavior in the data and then go investigate the behavioral and attitudinal drivers behind it through primary research. That triangulation approach is where I see the most compelling insights being generated.
On Ethical Challenges and Regulatory Compliance
Q: Healthcare research involves sensitive populations and highly regulated environments. How do you navigate the ethical dimensions?
Institutional Review Board (IRB) compliance is table stakes — but ethics in healthcare research goes well beyond regulatory checkboxes. Recruiting patients with serious or terminal diagnoses, for example, demands extraordinary care in screener design and interview facilitation. The risk of research fatigue, emotional burden, and — in rare cases — therapeutic misconception, where research participants confuse research participation with clinical care, are real concerns that responsible researchers must actively design against.
I'm also deeply conscious of the power dynamics inherent in physician research. Doctors are time-constrained, increasingly surveyed-out, and often skeptical of commercial research. Building research designs that respect their expertise, offer meaningful honoraria calibrated to their opportunity cost, and deliver genuinely interesting intellectual content as part of the research experience — rather than just extracting data — is how you build the physician panel trust that makes quality research possible.
On the Future of Healthcare Market Research
Q: Where do you see the field in five years?
AI-assisted analysis is going to be transformative, but I want to push back on the hype cycle a bit. Large language models are genuinely excellent at thematic coding, transcript summarization, and identifying patterns across large qualitative datasets. They are not yet reliable enough to replace the human interpretive layer that gives healthcare research its clinical and strategic meaning. The researchers who will thrive are those who use AI as a force multiplier for their domain expertise — not those who abdicate interpretation to the algorithm.
I also expect to see continued growth in patient engagement research driven by the increasing influence of patient advocacy organizations. Groups like the National Patient Advocate Foundation and disease-specific organizations are increasingly sophisticated research partners, and their involvement improves both the quality and the ethical standing of healthcare market research.
Closing Thoughts
Dr. Mehta's perspective reflects a sector that is intellectually demanding, ethically complex, and commercially critical. For market researchers considering healthcare as a specialization, her advice is clear: invest in domain knowledge, commit to methodological rigor, and never lose sight of the patient at the center of every research question. The global healthcare market — projected to reach $11.9 trillion by 2027 (Deloitte) — demands nothing less.